Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Monika Koziolek is active.

Publication


Featured researches published by Monika Koziolek.


Postepy Higieny I Medycyny Doswiadczalnej | 2014

Association of plasma hormones, nutritional status, and stressful life events in anorexia nervosa patients.

Małgorzata Śmiarowska; Krzysztof Safranow; Violetta Dziedziejko; Monika Białecka; Monika Koziolek; Jerzy Samochowiec

OBJECTIVE The aim of the current study was to analyze the relationships between plasma hormones, body weight parameters and stressful life events in anorexia nervosa (AN). MATERIAL AND METHODS 72 females in the active phase of AN were evaluated. 52 healthy women constituted the control group. RIA kits were used to measure plasma hormone levels. RESULTS The concentrations of leptin, insulin, IGF-1, triiodothyronine, LH, FSH, estradiol, and testosterone were significantly lower and those of cortisol and growth hormone significantly higher in the AN than the control group. No hormonal differences between restrictive and binge-purging AN subtypes were found. Leptin, IGF-1, gonadotropins, and sex steroids correlated significantly negatively and growth hormone positively with total reduction of body weight or the degree of undernutrition. Associations were also found between lower insulin concentration and family violence, lower cortisol and psychiatric diseases in the family, higher testosterone and patients alcohol or drug abuse. DISCUSSION The changed activity of the somatotropin-somatomedin, gonadal, and corticotrophin axes corresponds to the clinical stage of AN. Plasma IGF-1 seems to be the most sensitive and useful independent hormonal marker of cachexia.


Thyroid Research | 2014

New insights into the diagnosis of nodular goiter.

Anhelli Syrenicz; Monika Koziolek; Andrzej Ciechanowicz; Anna Sieradzka; Agnieszka Bińczak-Kuleta; Miłosz Parczewski

Preoperative diagnostic investigations of nodular goiter are based on two main examinations: ultrasonography of the thyroid gland and ultrasound-guided fine-needle aspiration biopsy. So far, FNAB has been the best method for the differentiation of nodules, but in some cases it fails to produce a conclusive diagnosis. Some of the biopsies do not provide enough material to establish the diagnosis, in some other biopsies cytological picture is inconclusive.Determining the eligibility of thyroid focal lesions for surgery has been more and more often done with molecular methods. The most common genetic changes leading to the development of thyroid cancer include mutations, translocations and amplifications of genes, disturbances in gene methylation and dysregulation of microRNA. The mutations of Ras proto-oncogenes and BRAF gene as well as disturbances of DNA methylation in promoter regions of genes regulating cell cycle (e.g. hypermethylation of RASSF1A gene and TIMP-3 gene) play an important role in the process of neoplastic transformation of thyreocyte. The advances in molecular biology made it possible to investigate these genetic disturbances in DNA and/or RNA from peripheral blood, postoperative thyroid tissue material and cytology specimens obtained through fine-needle aspiration biopsy of focal lesions in the thyroid gland.As it became possible to analyze the mutations and methylation of genes from cell material obtained through fine-needle aspiration biopsy, it would be beneficial to introduce the techniques of molecular biology in the pre-operative diagnosis of nodular goiter as a valuable method, complementary to ultrasonography and FNAB. The knowledge obtained from molecular studies might help to determine the frequency of follow-up investigations in patients with nodular goiter and to select patients potentially at risk of developing thyroid cancer, which would facilitate their qualification for earlier strumectomy.


Hormone and Metabolic Research | 2015

Prevalence and Clinical Outcome of CYP21A2 Gene Mutations in Patients with Nonfunctional Adrenal Incidentalomas.

Bartosz Kiedrowicz; Agnieszka Bińczak-Kuleta; J. Lubikowski; Monika Koziolek; Elżbieta Andrysiak-Mamos; M. Ostanek-Panka; Andrzej Ciechanowicz; Anhelli Syrenicz

Adrenal tumors, discovered incidentally in approximately 4.5% of imaging procedures, are known as adrenal incidentalomas. Nonclassic congenital adrenal hyperplasia, mild form of 21-hydroxylase deficiency, may lead to the development of adrenocortical tumors. The aim of the study was to evaluate prevalence of the most common nonclassic mutations of CYP21A2 gene in patients with adrenal incidentalomas and investigate possible relationship with clinical outcome. One hundred adult patients with such lesions were enrolled. Clinical, imaging and biochemical evaluation were performed to rule out hormonal overproduction or potential malignancy. All subjects and a control group of 100 neonates were genotyped for P30L, P453S, and V281L mutations of CYP21A2 gene using direct sequencing. Clinical and imaging features as well as hormone levels were analyzed. Heterozygous CYP21A2 gene mutations were detected in 8 subjects but not in the neonates. Thus, the risk of carrying mutant allele was significantly higher in subjects with adrenal tumors (OR=8.7; 95% CI=2.23-389.56; p=0.003). Mean concentrations of renin, basal, and stimulated 17-hydroxyprogesterone were higher and ACTH was lower in the carriers than in the remaining subjects. Furthermore, the carriers had higher incidence of hypertension (100 vs. 52.1%, p=0.008) and diabetes (50 vs. 11.9%, p=0.003). ACTH-stimulated 17-hydroxyprogesterone levels varied widely among the carriers. In summary, prevalence of P30L, P453S, and V281L mutations of CYP21A2 gene is increased in patients with adrenocortical tumors. In these subjects, carrying the analyzed mutant alleles may increase the risk of diabetes and hypertension. ACTH-stimulation test does not satisfactorily predict presence of heterozygous CYP21A2 mutations in patients with adrenal tumors.


Thyroid Research | 2014

From the diagnostic investigations of goiter to the diagnosis of lung cancer - case study.

Monika Koziolek; Anna Sieradzka; Lilianna Osowicz-Korolonek; Ewa Wentland-Kotwicka; Katarzyna Karpińska-Kaczmarczyk; Anhelli Syrenicz

Thyroid metastases account for approximately 1.4-3% of all malignancies of the thyroid gland. Thyroid metastases are most common in: clarocellular carcinoma of the kidney, lung cancer, breast cancer, malignant melanoma and cancers of gastrointestinal tract. A rare situation is when thyroid metastasis is diagnosed before detecting primary malignant focus and when it is the first manifestation of underlying disease. We present a case of 64-year-old male with thyroid metastasis being the first manifestation of lung adenocarcinoma.The authors emphasize that patients with the history of malignancy should undergo an ultrasound examination of the thyroid gland in order to exclude a focal lesion, and if such lesion is detected, fine-needle aspiration biopsy is recommended. The authors also point out that establishing final diagnosis of thyroid metastasis of cancer in other organs is only possible on the basis of postoperative histopathology and immunohistochemistry.


Endokrynologia Polska | 2015

Frequency assessment of BRAF mutation, KRas mutation, and RASSF1A methylation in nodular goitre based on fine-needle aspiration cytology specimens

Monika Koziolek; Agnieszka Bińczak-Kuleta; Maria Stepaniuk; Miłosz Parczewski; Elżbieta Andrysiak-Mamos; Anna Sieradzka; Krzysztof Safranow; Lilianna Osowicz-Korolonek; Bartosz Kiedrowicz; Andrzej Kram; Andrzej Ciechanowicz; Anhelli Syrenicz

INTRODUCTION Standard pre-operative diagnosis of nodular goitre is not always conclusive. The decision about nodular goitre surgery is increasingly based on molecular methods. The aim of the study was to determine BRAF T1799A mutation and KRas proto-oncogene mutation, and the analysis of RASSF1A promoter methylation level in cytological material obtained from FNAB specimens of thyroid nodules. MATERIAL AND METHODS The study population consisted of 85 women and 12 men. The study material was genomic DNA isolated from peripheral blood and thyroid bioptates. Pyrosequencing was used for the evaluation of RASSF1 methylation level. KRas mutation was investigated with Sanger sequencing. BRAF mutation was analysed by standard methods of real-time amplification detection (real-time PCR) with the use of specific starters surrounding the mutated site. RESULTS A significant positive correlation was demonstrated between mean methylation of four CpG islands of RASSF1A gene and thyroid tumour volume and its largest diameter (p < 0.05). KRas mutation was not detected in any of the 97 patients. In 7/85 subjects (8.2%) BRAF mutation was observed. In 6/7 patients with BRAF mutation, FNAB of thyroid nodules confirmed a benign nature of the lesions; the material was non-diagnostic in one patient, and papillary thyroid cancer was diagnosed on the basis of postoperative histopathology assessment. CONCLUSIONS The results of genetic tests reported in our study indicate that the presence of BRAF mutation or higher RASSF1A methylation levels in FNAB cytology specimens of benign lesions may be useful in the assessment of oncological risk, while the evaluation of KRas proto-oncogene mutation is not a valuable test in pre-operative diagnosis of nodular goitre.


Endokrynologia Polska | 2015

Frequency assessment of BRAF mutation, KRas mutation, and RASSF1A methylation in nodular goitre based on fine-needle aspiration cytology specimens Ocena częstości występowania mutacji genów BRAF, KRas oraz.

Monika Koziolek; Agnieszka Bińczak-Kuleta; Maria Stepaniuk; Miłosz Parczewski; Elżbieta Andrysiak-Mamos; Anna Sieradzka; Krzysztof Safranow; Lilianna Osowicz-Korolonek; Bartosz Kiedrowicz; Andrzej Kram; Andrzej Ciechanowicz; Anhelli Syrenicz

INTRODUCTION Standard pre-operative diagnosis of nodular goitre is not always conclusive. The decision about nodular goitre surgery is increasingly based on molecular methods. The aim of the study was to determine BRAF T1799A mutation and KRas proto-oncogene mutation, and the analysis of RASSF1A promoter methylation level in cytological material obtained from FNAB specimens of thyroid nodules. MATERIAL AND METHODS The study population consisted of 85 women and 12 men. The study material was genomic DNA isolated from peripheral blood and thyroid bioptates. Pyrosequencing was used for the evaluation of RASSF1 methylation level. KRas mutation was investigated with Sanger sequencing. BRAF mutation was analysed by standard methods of real-time amplification detection (real-time PCR) with the use of specific starters surrounding the mutated site. RESULTS A significant positive correlation was demonstrated between mean methylation of four CpG islands of RASSF1A gene and thyroid tumour volume and its largest diameter (p < 0.05). KRas mutation was not detected in any of the 97 patients. In 7/85 subjects (8.2%) BRAF mutation was observed. In 6/7 patients with BRAF mutation, FNAB of thyroid nodules confirmed a benign nature of the lesions; the material was non-diagnostic in one patient, and papillary thyroid cancer was diagnosed on the basis of postoperative histopathology assessment. CONCLUSIONS The results of genetic tests reported in our study indicate that the presence of BRAF mutation or higher RASSF1A methylation levels in FNAB cytology specimens of benign lesions may be useful in the assessment of oncological risk, while the evaluation of KRas proto-oncogene mutation is not a valuable test in pre-operative diagnosis of nodular goitre.


Endokrynologia Polska | 2015

Ocena częstości występowania mutacji genów BRAF, KRas oraz metylacji genu RASSF1A w wolu guzkowym na podstawie badania materiału cytologicznego uzyskanego drogą biopsji aspiracyjnej cienkoigłowej

Monika Koziolek; Agnieszka Bińczak-Kuleta; Maria Stepaniuk; Miłosz Parczewski; Elżbieta Andrysiak-Mamos; Anna Sieradzka; Krzysztof Safranow; Lilianna Osowicz-Korolonek; Bartosz Kiedrowicz; Andrzej Kram; Andrzej Ciechanowicz; Anhelli Syrenicz

INTRODUCTION Standard pre-operative diagnosis of nodular goitre is not always conclusive. The decision about nodular goitre surgery is increasingly based on molecular methods. The aim of the study was to determine BRAF T1799A mutation and KRas proto-oncogene mutation, and the analysis of RASSF1A promoter methylation level in cytological material obtained from FNAB specimens of thyroid nodules. MATERIAL AND METHODS The study population consisted of 85 women and 12 men. The study material was genomic DNA isolated from peripheral blood and thyroid bioptates. Pyrosequencing was used for the evaluation of RASSF1 methylation level. KRas mutation was investigated with Sanger sequencing. BRAF mutation was analysed by standard methods of real-time amplification detection (real-time PCR) with the use of specific starters surrounding the mutated site. RESULTS A significant positive correlation was demonstrated between mean methylation of four CpG islands of RASSF1A gene and thyroid tumour volume and its largest diameter (p < 0.05). KRas mutation was not detected in any of the 97 patients. In 7/85 subjects (8.2%) BRAF mutation was observed. In 6/7 patients with BRAF mutation, FNAB of thyroid nodules confirmed a benign nature of the lesions; the material was non-diagnostic in one patient, and papillary thyroid cancer was diagnosed on the basis of postoperative histopathology assessment. CONCLUSIONS The results of genetic tests reported in our study indicate that the presence of BRAF mutation or higher RASSF1A methylation levels in FNAB cytology specimens of benign lesions may be useful in the assessment of oncological risk, while the evaluation of KRas proto-oncogene mutation is not a valuable test in pre-operative diagnosis of nodular goitre.


Current Issues in Pharmacy and Medical Sciences | 2014

Diagnostic problems with follicular thyroid cancer – case study

Monika Koziolek; Anna Sieradzka; Michal Jakuszewski; Lilianna Osowicz-Korolonek; Katarzyna Karpińska-Kaczmarczyk; Anhelli Syrenicz

Abstract The diagnosis of follicular thyroid cancer is based on postoperative histopathology assessment. In its minimally invasive form, the signs of vascular invasion and capsular infiltration may sometimes be seen only in a small tumor fragment; hence, the diagnosis should be based on multiple histopathology specimens. This case study is a report on a 70-year-old female who was diagnosed with spinal metastasis of follicular thyroid cancer. This diagnosis was established 5 years after partial strumectomy due to goiter and there were no signs of thyroid cancer in postoperative histopathology assessment. Based on this case and literature reports, the authors conclude that the diagnosis of follicular thyroid cancer, especially its minimally invasive forms, may pose a diagnostic problem even when based on postoperative histopathology.


Thyroid Research | 2013

Metastasis to the thyroid gland as the first clinical manifestation of lung cancer – case report

Monika Koziolek; Anna Sieradzka; Ewa Wentland-Kotwicka; M Machaj; A Makszewska; A Dubińska-Walczak; Anhelli Syrenicz

The incidence of metastatic thyroid tumours range from 2 to 3% of all thyroid cancer cases. Histological and immunohistochemical examination plays a decisive role in metastasis recognition. Metastases to the thyroid gland are rarely identified in cytological diagnostics. Patients who were postoperatively recognized with metastasis to the thyroid gland were diagnosed in cytological results as follicular tumour, cancer or atypical cells. We present a case of a 64-year-old male, who was diagnosed with lung adenocarcinoma based on diagnostics of a nodular change in the thyroid gland.


Thyroid Research | 2013

Diagnosis of follicular thyroid cancer based on the presence of a metastasis in the vertebral column – case report

Monika Koziolek; M Wolska; Anna Sieradzka; M Jakuszewski; Katarzyna Karpińska-Kaczmarczyk; M Bilski; Anhelli Syrenicz

Follicular thyroid cancer, similar to follicular adenoma, usually takes the form of a round, encapsulated tumour. Cytological examination does not allow a firm diagnosis of follicular thyroid cancer to be made. Follicular thyroid cancer can be diagnosed by histopathological examination only after demonstrating the infiltration of the capsule by the tumour and/or vessel invasion. The tumour spreads mainly through the bloodstream causing metastasis to the lungs and bones. We present a case of a 70-year-old woman who has been diagnosed with a follicular thyroid carcinoma based on the presence of a metastasis to the bones.

Collaboration


Dive into the Monika Koziolek's collaboration.

Top Co-Authors

Avatar

Anhelli Syrenicz

Pomeranian Medical University

View shared research outputs
Top Co-Authors

Avatar

Anna Sieradzka

Pomeranian Medical University

View shared research outputs
Top Co-Authors

Avatar

Bartosz Kiedrowicz

Pomeranian Medical University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Andrzej Ciechanowicz

Pomeranian Medical University

View shared research outputs
Top Co-Authors

Avatar

Krzysztof Safranow

Pomeranian Medical University

View shared research outputs
Top Co-Authors

Avatar

Miłosz Parczewski

Pomeranian Medical University

View shared research outputs
Top Co-Authors

Avatar

Maria Stepaniuk

Pomeranian Medical University

View shared research outputs
Researchain Logo
Decentralizing Knowledge